Effect of Saroglitazar on Glycemic Status: A Meta-analysis
Our meta-analysis has found that saroglitazar causes a significant reduction in the HbA<sub>1c</sub>, FBS, and PPBS levels in patients treated for diabetic dyslipidemia.
Authors
- Sandhiya Selvarajan (ORCID: https://orcid.org/0000-0002-7948-7821)
- Anandabaskar Nishanthi
- Melvin George (ORCID: https://orcid.org/0000-0001-7101-8513)
- Santhosh Shivabasappa (ORCID: https://orcid.org/0000-0001-7871-1038)
- Ilanthamizhan Jayakumar
- Shravan Venkatraman (ORCID: https://orcid.org/0000-0002-4376-7960)
- Sadishkumar Kamalanathan (ORCID: https://orcid.org/0000-0002-2371-0625)
- Jayaprakash Sahoo
Institutions
- Sri Ramachandra Institute of Higher Education and Research (IN)
- Hindu Mission Hospital (IN)
- Indra (Spain) (ES)
- ACS Medical College and Hospital (IN)
- Sri Ramachandra Medical Centre (IN)
- Sri Manakula Vinayagar Medical College and Hospital (IN)
- Jawaharlal Institute of Post Graduate Medical Education and Research (IN)
Publication Details
- Journal
- Cureus
- Published
- 2025-12-13
- DOI
- https://doi.org/10.7759/cureus.99122
- Primary Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Type
- article
- Field-Weighted Citation Impact
- 0.00